Symbol="ARGX"
AssetType="Common Stock"
Name="argenx NV ADR"
Description="argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands."
CIK="1697862"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="INDUSTRIEPARK ZQIJNAARDE 7, BUILDING C B-9052, ZWIJNAARDE, BE"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="21623982000"
EBITDA="-479285760"
PERatio="None"
PEGRatio="0"
BookValue="2.032"
DividendPerShare="0"
DividendYield="0"
EPS="-9.19"
RevenuePerShareTTM="0.463"
ProfitMargin="-0.8"
OperatingMarginTTM="-0.946"
ReturnOnAssetsTTM="-0.151"
ReturnOnEquityTTM="-0.265"
RevenueTTM="639411000"
GrossProfitTTM="-251786000"
DilutedEPSTTM="-9.19"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="6.3"
AnalystTargetPrice="474"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="78.22"
PriceToBookRatio="7.24"
EVToRevenue="72.3"
EVToEBITDA="-21.25"
Beta="0.429"
num_52WeekHigh="423.99"
num_52WeekLow="333.07"
num_50DayMovingAverage="396.73"
num_200DayMovingAverage="378.14"
SharesOutstanding="55678000"
DividendDate="None"
ExDividendDate="None"
symbol="ARGX"
open="383.14"
high="389.58"
low="383.14"
price="386.51"
volume="127940.00"
latest_trading_day="2023-07-10"
previous_close="382.73"
change="3.78"
change_percent="0.9876%"
aroon_positive_momentum_days="58"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="58"
Volume_recent_avg="216436"
Change_recent_avg="0.6"
Delta_recent_avg="7.83"
Variance_recent_avg="3.92"
Change_ratio_recent_avg="0.15"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="58"
Aroon_momentum_negative="42"
image_negative_thumbnail_id_1="1161"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0195.jpeg"
image_negative_thumbnail_id_2="113"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0063.jpeg"
image_neutral_thumbnail_id_1="568"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0031.jpeg"
image_neutral_thumbnail_id_2="586"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0013.jpeg"
image_positive_thumbnail_id_1="692"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0016.jpeg"
image_positive_thumbnail_id_2="956"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0118.jpeg"
image_professor_thumbnail_id_1="1196"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
image_professor_thumbnail_id_2="1186"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0020.jpeg"
